sorafenib has been researched along with fluorodeoxyglucose f18 in 21 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (fluorodeoxyglucose f18) | Trials (fluorodeoxyglucose f18) | Recent Studies (post-2010) (fluorodeoxyglucose f18) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 34,771 | 2,160 | 20,111 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (14.29) | 29.6817 |
| 2010's | 16 (76.19) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Araki, K; Ebi, H; Kawada, K; Kim, YI; Kitagawa, K; Minami, H; Mukai, H; Nakajima, H; Nakajima, K; Tahara, M | 1 |
| Brouwers, AH; Hospers, GA; Mulder, NH; Siemerink, EJ | 1 |
| Boijsen, M; Lundstam, S; Lyrdal, D; Stierner, U; Suurküla, M | 1 |
| Ambrosini, V; D'Errico-Grigioni, A; Fanti, S; Fini, M; Franchi, R; Giavaresi, G; Malvi, D; Nanni, C; Quarta, C; Torricelli, P; Zinzani, PL | 1 |
| El-Deiry, WS; Ferrara, TA; Katz, SI; Mayes, PA; Smith, CD; Wang, W; Zhou, L | 1 |
| Caponigro, F; Ciarmiello, A; Milano, A; Perri, F | 1 |
| Ahn, SH; Choi, HJ; Han, KH; Kim, DY; Lee, JD; Lee, JH; Park, JY; Seo, HJ | 1 |
| Hayashi, N; Ikeda, I; Inoue, T; Kishida, T; Kobayashi, K; Kubota, Y; Makiyama, K; Minamimoto, R; Miura, T; Murakami, T; Nakaigawa, N; Noguchi, S; Ohgo, Y; Sano, F; Tateishi, U; Ueno, D; Yao, M | 1 |
| Cowey, CL; Gohil, H; Khandani, AH; Moore, DT; Rathmell, WK | 1 |
| Aide, N; Bardet, S; Crouzeix, G; Michels, JJ; Sevin, E; Vaur, D | 1 |
| Camera, L; Colao, A; Del Prete, M; Esposito, R; Faggiano, A; Fonti, R; Marotta, V; Palmieri, G; Ramundo, V; Salvatore, M; Vitale, M | 1 |
| Levra, MG; Novello, S; Pelosi, E; Scagliotti, GV; Solitro, F; Vavalà, T; Veltri, A | 1 |
| Banzo, I; Carril, JM; Martínez-Rodríguez, I | 1 |
| Ameye, L; Awada, A; Flamen, P; Garcia, C; Lalami, Y; Paesmans, M | 1 |
| Abrantes, AM; Botelho, MF; Brito, AF; Casalta-Lopes, JE; Gonçalves, AC; Laranjo, M; Mamede, AC; Ribeiro, M; Sarmento-Ribeiro, AB; Tralhão, JG | 1 |
| Ameye, L; Delaunoit, T; Deleporte, A; Demolin, G; Flamen, P; Garcia, C; Gauthier, N; Guiot, T; Hendlisz, A; Holbrechts, S; Lhommel, R; Maréchal, R; Van den Eynde, M; Vierasu, I; Woff, E | 1 |
| Cho, A; Choi, YD; Hwang, SH; Kang, WJ; Rha, SY; Yun, M | 1 |
| Bao, B; Delaney, J; Groves, K; Ho, G; Kossodo, S; Morin, J; Narayanan, N; Peterson, JD; Rajopadhye, M; Tseng, JC; Zhang, J | 1 |
| Bae, SH; Choi, JY; Hwang, S; Jang, JW; Park, HL; Song, MJ; Sung, PS; Yang, K; Yoo, IR; Yoon, SK | 1 |
| Abdulla, DSY; Backes, H; Behringer, D; Buettner, R; Eichstaedt, M; Fischer, RN; Franklin, J; Frechen, S; Fuhr, U; Gardizi, M; Junge, L; Kaminsky, B; Kinzig, M; Kobe, C; Limburg, M; Mattonet, C; Merkelbach-Bruse, S; Michels, S; Nogova, L; Ouyang, D; Persigehl, T; Rokitta, D; Scheffler, M; Schnell, R; Sörgel, F; Sos, ML; Stelzer, C; Suleiman, AA; Taubert, M; Tian, Y; Wolf, J | 1 |
| Akutsu, N; Hirano, T; Ishigami, K; Kawakami, Y; Nakase, H; Numata, Y; Sasaki, S; Wagatsuma, K | 1 |
1 review(s) available for sorafenib and fluorodeoxyglucose f18
| Article | Year |
|---|---|
Targeted-therapy and imaging response: a new paradigm for clinical evaluation?
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Clinical Trials as Topic; Diagnostic Imaging; Fluorodeoxyglucose F18; Humans; Imatinib Mesylate; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Radiopharmaceuticals; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2011 |
7 trial(s) available for sorafenib and fluorodeoxyglucose f18
| Article | Year |
|---|---|
Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Extracellular Signal-Regulated MAP Kinases; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2008 |
Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography.
Topics: Aged; Benzenesulfonates; Carcinoma, Renal Cell; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; Sorafenib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Primary renal cell carcinoma: relationship between 18F-FDG uptake and response to neoadjuvant sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Biological Transport; Carcinoma, Renal Cell; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Kidney Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; Safety; Sorafenib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2012 |
Early response to chemotherapy in patients with non-small-cell lung cancer assessed by [18F]-fluoro-deoxy-D-glucose positron emission tomography and computed tomography.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Niacinamide; Paclitaxel; Phenylurea Compounds; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Sorafenib; Tomography, X-Ray Computed | 2013 |
Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early fluorodeoxyglucose positron emission tomography-CT response to outcome in patients with recurrent and/or metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Sorafenib; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Drug Monitoring; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Treatment Outcome | 2016 |
Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Everolimus; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Proto-Oncogene Proteins p21(ras); Sorafenib | 2020 |
13 other study(ies) available for sorafenib and fluorodeoxyglucose f18
| Article | Year |
|---|---|
18F-Fluorodeoxyglucose positron emission tomography for monitoring response to sorafenib treatment in patients with hepatocellular carcinoma.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyridines; Radiopharmaceuticals; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2008 |
18[F]FDG small animal PET study of sorafenib efficacy in lymphoma preclinical models.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Drug Evaluation, Preclinical; Fluorodeoxyglucose F18; Humans; Lymphoma; Mice; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Prognosis; Pyridines; Radiopharmaceuticals; Sorafenib; Treatment Outcome | 2010 |
FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cisplatin; Disease Models, Animal; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; Recombinant Proteins; Sorafenib; TNF-Related Apoptosis-Inducing Ligand; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2011 |
Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; Radiopharmaceuticals; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Survival Rate; Time Factors; Treatment Outcome; Young Adult | 2011 |
Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course.
Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Renal Cell; Female; Fluorodeoxyglucose F18; Humans; Indoles; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Unusual short-term complete response to two regimens of cytotoxic chemotherapy in a patient with poorly differentiated thyroid carcinoma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cisplatin; Combined Modality Therapy; Doxorubicin; Fatal Outcome; Female; Fluorodeoxyglucose F18; Humans; Indoles; Iodine Radioisotopes; Lung Neoplasms; Middle Aged; Niacinamide; Paclitaxel; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Radiopharmaceuticals; Sorafenib; Sunitinib; Thyroid Neoplasms; Thyroidectomy; Tomography, X-Ray Computed | 2012 |
Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET.
Topics: Antineoplastic Agents; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Retrospective Studies; Sorafenib; Thyroglobulin; Thyroid Neoplasms; Treatment Outcome | 2013 |
Metabolic response demonstrated by 18F-FDG-PET/CT in metastatic medullary thyroid carcinoma under sorafenib therapy.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Biomarkers, Tumor; Carcinoma, Neuroendocrine; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Multimodal Imaging; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Sorafenib; Thyroid Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
New Approach for Treatment of Primary Liver Tumors: The Role of Quercetin.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Survival; DNA Damage; Fluorodeoxyglucose F18; Glucose Transporter Type 1; Hep G2 Cells; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Quercetin; Sorafenib; Tumor Suppressor Protein p53 | 2016 |
Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Positron Emission Tomography Computed Tomography; Pyrimidines; Pyrroles; Radiopharmaceuticals; Sorafenib; Sulfonamides; Sunitinib | 2017 |
Fluorescence imaging of bombesin and transferrin receptor expression is comparable to 18F-FDG PET in early detection of sorafenib-induced changes in tumor metabolism.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Fluorescent Dyes; Fluorodeoxyglucose F18; Humans; Mice, Transgenic; Molecular Imaging; Neoplasm Transplantation; Niacinamide; Optical Imaging; Phenylurea Compounds; Positron-Emission Tomography; Radiopharmaceuticals; Random Allocation; Receptors, Bombesin; Receptors, Transferrin; Sorafenib; Treatment Outcome; Tumor Burden | 2017 |
Topics: Carcinoma, Hepatocellular; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Positron Emission Tomography Computed Tomography; Retrospective Studies; Sorafenib; Treatment Outcome | 2018 |
A case of hepatocellular carcinoma with long-term survival by multidisciplinary treatment for cranial and skeletal muscle metastases.
Topics: Carcinoma, Hepatocellular; Drugs, Investigational; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Muscle, Skeletal; Skull; Sorafenib; Tegafur | 2022 |